Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

ON-TREATMENT LDL-C LEVELS WHEN ALIROCUMAB DOSE IS DECREASED FROM 150 TO 75 MG EVERY 2 WEEKS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM ODYSSEY OLE

Michel Farnier,John Guyton,Gisle Langslet,Robert Dufour,Marie Baccara-Dinet,Chantal Din-Bell,Garen Manvelian,G. Kees Hovingh

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2017）

Cited 0|Views9
No score
Abstract
Background: Alirocumab (ALI) is available in two doses, 75 and 150 mg (to be administered once every 2 weeks [Q2W]). ODYSSEY LONG TERM was a 78-week double-blind trial of ALI 150 mg Q2W versus placebo, as add-on to maximally tolerated statin ± other lipid-lowering therapy (LLT). Patients with
More
Translated text
Key words
heterozygous familial hypercholesterolemia,alirocumab dose,on-treatment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined